Miach Orthopaedics, Inc.
- Home
- Companies
- Miach Orthopaedics, Inc.
- Articles
- BEAR III Clinical - Case Study
BEAR III Clinical - Case Study
Dec. 7, 2022
Courtesy ofMiach Orthopaedics, Inc.
The BEAR Implant is the first medical advancement to enable your body to heal its own torn anterior cruciate ligament (ACL). That’s a big deal, because until now your ACL would have been replaced with either another tendon from your body or a tendon from a deceased donor. The BEAR Implant is different because it works with your own blood to heal the torn ends of your ACL back together.
Most popular related searches
The BEAR Implant was approved by the U.S. Food and Drug Administration in 2020, and Miach continues to expand its base of evidence through post-market and label expansion studies. BEAR III is a multi-center study in which all participants will receive the BEAR Implant to treat their ACL tears.
This study is enrolling 250 participants who:
- Are 12-80 years of age
- Had an ACL tear within 50 days of the expected surgery date
- Have a BMI less than 35 kg/m2